The distribution and chromatographic characterization of PHI (peptide histidine isoleucine amide)-27-like peptides in rat and porcine brain by Beinfeld, M.C. et al.
0270-6474/84/0411-2681$02.00/O The Journal of Neuroscience 
Copyright 0 Society for Neuroscience Vol. 4, No. 11, pp. 2681-2688 
Printed in U.S.A. November 1984 
THE DISTRIBUTION AND CHROMATOGRAPHIC CHARACTERIZATION 
OF PHI (PEPTIDE HISTIDINE ISOLEUCINE AMIDE)-27-LIKE 
PEPTIDES IN RAT AND PORCINE BRAIN1 
MARGERY C. BEINFELD,’ DIANA M. KORCHAK, BRYAN L. ROTH,* AND T. L. O’DONOHUES 
Department of Pharmacology, St. Louis University, St. Louis, Missouri 63104; * Department of Psychiatry, Naval Medical 
Hospital, Bethesda, Maryland 20814 and Laboratory of Preclinical Pharmacology, National Institute of Mental Health, 
Washington, D.C. 20032; and $ Experimental Therapeutics Branch, National Institute of Neurological and Communicative 
Disorders and Stroke, National Institutes of Health, Bethesda, Maryland 20205 
Received October 28,1983; Revised February 27,1984; Accepted April 12, 1984 
Abstract 
This study was initiated to characterize PHI (peptide histidine isoleucine amide)-27-like peptides (PLPs) in 
rat and porcine brain in comparison with other members of the vasoactive intestinal polypeptide (VIP) family 
and to investigate their distribution by radioimmunoassay. 
The peptidic nature of the rat brain PLP was indicated by its trypsin sensitivity. On Sephadex chromatog- 
raphy rat brain PLP has the same molecular weight as synthetic (porcine intestinal) PHI-27. High pressure 
liquid chromatographic separations revealed that PLP in rat and porcine brain extracts elutes as a single peak 
distinct from VIP or secretin. Porcine brain PLP elutes in the same position as synthetic PHI-27, whereas rat 
brain PLP immunoreactivity consistently separates from synthetic PHI-27. This suggests that porcine brain 
PLP is identical to synthetic PHI-27, in agreement with the reported sequence of Tatemoto et al. (Tatemoto, 
K., M. Carlquist, T. McDonald, and V. Mutt (1983) FEBS Lett. 153: 248-252), whereas PLP may have a 
different amino acid sequence (or may be post-translationally modified). 
Using specific PHI and VIP radioimmunoassays, the distribution of PLP was found to parallel that of VIP 
in rat and porcine brain, being highest in cerebral cortex, amygdala, and hippocampus. PLP, like VIP, is 
abundant in rat retina and can be included in the growing list of retinal peptides. This highly correlated 
distribution of VIP and PLP may be explained by the recent discovery that they are derived from the same 
precursor (Itoh, N., K. Obata, N. Yanaihara, and H. Okamoto (1983) Nature 304: 547-549). In some brain 
regions, however, the distribution of the two peptides was less strongly correlated, which perhaps could be 
explained by differential local regulation of gene translation or peptide processing. 
The closely correlated distribution of brain VIP and PLP and the known ability of PHI-27, like VIP, to 
activate adenylate cyclase (Jensen, R. T., K. Tatemoto, V. Mutt, G. Lemp, and J. Gardner (1982) Am. J. 
Physiol. 241: G498-G502; Watling, K. J., and J. E. Dowling (1983) J. Neurochem. 41: 1205-1213; Roth, B. L., 
M. C. Beinfeld, and A. C. Howlett (1984) J. Neurochem. 42: 1145-1152) and inhibit VIP binding (Jensen, R. 
T., K. Tatemoto, V. Mutt, G. Lemp, and J. Gardner (1982) Am. J. Physiol. 241: G498-G502; Robberecht, P., 
K. Tatemoto, P. Chatelain, M. Waelbroeck, M. Delhaye, G. Taton, P. DeNeff, J. Camus, J. C. Hause, and J. 
Christophe (1982) Regul. Pept. 4: 241-250) suggest that PLPs may play a role as endogenous modulators of 
VIP activity. 
Peptide histidine isoleucine amide (PHI)-27 was isolated activities in several tissues. It stimulates amylase secretion and 
from porcine intestine (Tatemoto and Mutt, 1981) and the elevates levels of CAMP in pancreatic acinar cells (Jensen et 
identical sequence was found in porcine brain (Tatemoto et al., al., 1982), lung membranes (Robberecht et al., 1982), rat neu- 
1983). This peptide has strong sequence homology with vaso- roblastoma cells (Roth et al., 1984), carp retinal pieces and 
active intestinal peptide (VIP), secretin, glucagon, gastric in- isolated horizontal cells (Watling and Dowling, 1983), and 
hibitory peptide, and newly discovered growth hormone-releas- intestinal epithelial cells, fat cells, and gastric glands (Bataille 
ing hormone (GHRH). PHI-27 has VIP- and secretin-like et al., 1980). Under some conditions PHI-27 is more potent 
than VIP in releasing prolactin from dispersed anterior pitui- 
tary cells and hemipituitaries of the rat (Werner et al., 1983). 
1 This work was supported by National Institutes of Health Grants Other VIP-like actions of PHI-27 have recently been summa- 
NS 18335 and NS 18667 and by a grant from the American Parkinson rized (Christofides et al., 1982a). PHI-27 can inhibit iz51-labeled 
Disease Association. We wish to thank Ms. Maggie Klevorn for expert VIP binding in these systems (although with lower affinity 
secretarial assistance. than VIP) and appears to activate adenylate cyclase via the 
* To whom correspondence should be addressed. VIP or secretin receptors in these tissues. 
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A PHI-like peptide (PLP) has been detected in rat, human, 
guinea pig, and cat brain and peripheral tissues by radioim- 
munoassay (RIA) (Christofides et al., 1982a, b, 1983). However, 
detailed descriptions of PLP’s distribution, chemical nature, 
chromatographic characteristics, and its relationship to other 
structurally related peptides in brain have not yet been re- 
ported. In preliminary reports, a striking similarity in the 
distribution of VIP and PLP was observed (Christofides et al., 
1982a). Immunocytochemical staining of central and peripheral 
tissues indicated that VIP and PLP were often co-localized in 
the same neurons, although Hokfelt et al. (1982) found this not 
to be true for the paraventricular nucleus and the median 
eminence. This close association of VIP and PLP has led to 
the suggestion that PLP and VIP might originate from the 
same precursor peptide. The cloning of the mRNA for VIP 
from a human neuroblastoma cell line has revealed the presence 
of an amino acid sequence which codes for a peptide very 
similar to PHI (25 of 27 amino acids the same) (Itoh, et al., 
1983). Whether the mRNA which codes for this PLP (called 
PHM-27) is the human equivalent of PHI or whether other 
mRNAs exit which code for PHI-27 in humans has not been 
determined. 
This study was initiated to examine in greater detail the 
chemical composition and chromatographic characteristics of 
PLP, its relationship to VIP and other chemically related brain 
peptides, and its distribution in rat and porcine brain. 
Materials and Methods 
PHI antiserum 
A specific antiserum against porcine PHI was obtained by immuniz- 
ing male New Zealand White rabbits with synthetic PHI-27 (Pennin- 
sula Laboratories) conjugated to bovine serum albumin with glutaral- 
dehyde. The conjugate was prepared by adding dropwise 3.5 ml of a 
solution of freshly prepared 22 mM glutaraldehyde to a mixture of 0.5 
mg of PHI-27 dissolved in 0.5 ml of phosphate buffer (0.05 mM, pH 
7.4) and 7.5 mg of bovine serum albumin dissolved in 1.2 ml of 0.38 M 
borate buffer, pH 8.5. The rabbits were injected at approximately 2- 
week intervals with conjugate containing 50 fig of PHI in Fruend’s 
complete adjuvant and were bled periodically, 3 days after immuniza- 
tion. The bleed used in the study (bleed 5) was obtained about 6 months 
after the beginning of the immunizations. 
PHI and VIP radioimmunoassays 
PHI and VIP were iodinated by the same procedure, and the labeled 
peptides were separated using a fibrous cellulose column (Christophe 
et al., 1976). The labeled peptides were stable for 3 to 4 weeks at -20°C. 
The PHI antiserum was used at a final dilution of 1:20,000 in a final 
assay volume of 0.5 ml using phosphate-buffered saline (PBS; 10 mM 
sodium phosphate, pH 7.4,0.15 M NaCl) containing 0.1% ethylmercur- 
ithiosalicylate and 25 mM EDTA. The assay employed a non-equilib- 
rium method in which antibody, buffer, and samples were incubated 
for 24 hr at 4°C iodinated peptide (4000 to 8000 cpm) was added, and 
the assay was stopped 16 to 18 hr later. Free and bound labeled peptide 
were separated by dextran-charcoal (5 gm of Decton-Dickinson RIA- 
grade Norit and 0.5 gm of Becton-Dickinson RIA-grade dextran/liter 
of PBS), 1 ml/tube, followed by centrifugation at 1,800 X g for 15 min. 
The supernatant was decanted and counted for 1 min in a Beckman 
8000 gamma counter interfaced with an Apple II+ computer. Results 
were calculated utilizing the National Institutes of Health RIA program 
of Rodbard and Munson (1980), which employs a nonlinear least 
squares approximation of the log-logit transformation. The National 
Institutes of Health RIA program as provided by Biomedical Comput- 
ing Technology Information Center, Vanderbilt University, Nashville, 
TN. 
The PHI assay can reliably detect 10 to 20 pg/tube, with an EDs0 to 
50 to 100 pg/tube. The antiserum cross-reacts weakly with secretin 
(0.8%), glucagon (0.05%), and PHM-27 (0.02%), but at 1 fig/tube it 
displays no cross-reactivity with any of the other peptides in the VIP- 
secretin family or with other unrelated neuropeptides tested (see Fig. 
1). 
VIP RIA. VIP RIA was performed as previously described (Eiden et 
al., 1982), using a VIP antiserum, N2-12 (kindly provided by Dr. G. 
Nilaver), with low cross-reactivity for PHI-27 (0.02%). It was used at 
a final dilution of 1:60,000. The VIP assay can reliably detect 2.5 to 5 
pg/tube, with an ED, of 15 to 25 pg/tube. 
Tissue dissection and extraction 
To determine the best extraction method for PLP from rat brain, 
several methods which work well for VIP were tested along with other 
methods which work well for other peptides. The results are shown in 
Table I. 
The porcine brains were dissected at the slaughterhouse, frozen on 
dry ice, extracted in boiling water, and centrifuged at 10,000 x g for 10 
min, and the pellets were re-extracted with 0.5 M acetic acid. The two 
supernatants were combined, dried down, resuspended, and assayed for 
PLP and VIP. 
For the gross dissection of rat brain, the rat brain was placed in a 
Plexiglas brain block and sliced with razor blades into l-mm slices, 
placed on iced glass slides, and dissected free-hand into the areas 
described. The dissected areas were frozen on dry ice and stored at 
-20°C until they were extracted by sonication in 0.1 N HCl. An aliquot 
was removed from each homogenate for Lowry protein determination 
(Lowry et al., 1951); the extracts then were clarified by centrifugation 
at 10,000 x g for 10 min. The 0.1 N HCl extracts were neutralized with 
an equal volume of 0.1 N NaOH prior to the VIP or PHI RIA. The 
micropunches were prepared by the method of Palkovits (1973) and 
were extracted as previously described (Beinfeld and Palkovits, 1982). 
Chromatography 
Sephadex 
A l.O-ml sample of 0.1 N HCl extract of rat brain (equivalent to one- 
tenth of a rat brain) was applied to a 1 x 100 cm column of Sephadex 
G-50 (Superfine) previously equilibrated with 1% (v/v) acetic acid. The 
elution of rat brain PLPs was compared with the elution of synthetic 
PHI. blue dextran (void volume marker). and Na? (included volume 
marker). Two-milliliter fractions were collected, and aliquots were 
removed and dried prior to the RIA. 
HPLC 
Three chromatographic systems were used to compare the elution of 
porcine and rat brain- VIP and PHI peptides. All employed a Varian 
5000 eouinned with an LDC Snectrometer III variable wavelength UV 
detector and were run at 1 mljmin with l-ml fractions collected. 
A. C18-TEAP system. This system utilized octadecylsilane (C18) 
column from Alltech (0.45 X 25 cm; 5-pm particle size) run with a 
linear gradient, lasting 60 min, from 20% to 60% acetonitrile in trieth- 
ylamine/phosphoric acid, pH 3.25. 
II. Cl%TFA system. This system used column run with a linear 
gradient, lasting 60 min, of 20% to 80% buffer B (acetoni- 
trile:water:trifluoracetic acid (TFA), 900:99:1, v/v/v, buffer A (wa- 
ter:TFA, 999:1, v/v). 
C. Phenyl-TFA system. This sytem utilized a Waters phenyl column 
(25 x 0.45 cm) and the same buffer system as in system B, with a 
gradient from 20 to 60% buffer B, lasting 60 min. 
Fractions were dried in a Savant vacuum centrifuge and assayed for 
PHI and VIP. The elution of VIP and PHI immunoreactivity in rat 
and porcine brain was compared to the elution of synthetic (porcine) 
VIP and PHI-27 optical activity and immunoreactivity. Standards were 
run before and after the brain samples, with extensive washing and 
blank injections of water in between to ensure that no carryover of 
standards into sample occurred. 
Protease digestion of PHI 
Trypsin (Sigma, type III, bovine pancreas, 11, 250 N-cr-benzoyl-L- 
arginine ethyl ester units/mg of protein) was added at a final concen- 
tration of 5 mg/ml to 1 ng of synthetic PHI or a volume of rat extract 
containing 1.4 ng of PHI-like immunoreactivity, in a final volume of 
1.6 ml containing 13 mM sodium phosphate, pH 7.6. The samples were 
incubated at 37”C, and aliquots were removed at 15, 30, and 45 min, 
boiled for 10 min, and assayed for PHI. 
Results 
Chemical composition of the PHI-like immunoreactive sub- 
stance in rat brain. When either a rat brain extract or synthetic 
PHI-27 was treated with trypsin, the PLP immunoreactivity 
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Figure 1. Immunological characterization of the PHI antiserum (P3) used in this study. P3 cross-reacts weakly with secretin (0.8%), glucagon 
(0.05%), and PHM-27 (0.02%) but displays no cross-reactivity with other structurally related peptides (VIP, gastric inhibitory peptide, motilin, 
and GHRH) or unrelated peptides (Leu-enkephalin, gastrin, or cholecystokinin-8) tested to 1 pg/ml. 
TABLE I 
The effect of different extraction methods on the recovery of PHI-like 
immunoreactivity from rat brain 
Rat brains were split sagittally into two equal pieces at the midline, 
frozen, weighed, and extracted individually by the different methods in 
groups of three, in a volume of 5.0 ml. All boiling steps were for 10 
min. Homogenization was performed with a Tekmar Ultra-Turrax 
homogenizer. In method 3, the re-extraction was at room temperature. 
In method 5, the tissue was homogenized in 75% acetone/22% (4.5% 
v/v) acetic acid. In methods 4 and 5, the extraction was done at room 
temperature. 
Extraction Method PHI 
nglgm of 
wet wt. 
1. Boiling water 
2. Boiling 0.5 M acetic acid 
3. Boiling water, re-extract pellet with 0.5 M 
acetic acid 
60 f 0.3 
206 f 16 
101 f 16 
4. 0.1 N HCl 
5. Acid/acetone 
249 + 36 
137 f 8 
was completely eliminated in 15 min. This indicates that PLP 
in rat brain is a peptide and that, like synthetic PHI-27, which 
is cleaved by trypsin into five fragments (Tatemoto and Mutt, 
1981), it has trypsin-sensitive basic residues in portions of the 
sequence where cleavage eliminates immunoreactivity. 
Sephudex chromatography of rat brain extracts. A rat brain 
extract was applied to a Sephadex G-50 column and the elution 
of PLP was determined (see Fig. 2). The majority of the PHI- 
like material eluted in the same position as synthetic PHI, 
although additional peaks appear with a higher apparent mo- 
lecular weight. These additional peaks could be either biosyn- 
thetic precursors to PLP, PLP aggregates, or other peptides 
with some degree of cross-reactivity with the PHI antiserum. 
Further experiments would be required to determine the iden- 
tity of this immunoreactive material. 
High pressure liquid chromatographic (HPLC) separation of 
PLP from rat and porcine brain. Rat and porcine extracts were 
subjected to HPLC separations as described under “Materials 
and Methods.” Three different systems were used, and since 
the data obtained on all of them were very similar, the data 
from only two systems are included. On all systems, rat and 
porcine brain PLP elutes as a single major peak separated from 
secretin and VIP. Porcine brain PLP co-elutes with synthetic 
PHI-27 as would be expected, whereas rat brain PLP elutes 
three to four fractions before synthetic PHI-27, indicating that 
it is less hydrophobic. VIP-like immunoreactivity in both por- 
cine and rat brain co-elutes with synthetic VIP, in agreement 
with sequence data on VIP in these two species (Said and Mutt, 
1970; Dimaline et al., 1983) (Fig. 3). There is an additional 
smaller peak of VIP immunoreactivity which elutes near secre- 
tin in rat and porcine brain. Since the VIP antiserum has no 
cross-reactivity with secretin when tested at 1 pg/assay tube, it 
is unlikely that it is secretin. A minor peak of PLP also occurs 
in the same location in porcine brain but not in rat brain. 
Based on the secretin content of brain and the low cross- 
reactivity of the PHI antiserum for secretin, it is unlikely that 
this peak is secretin. The nature of this peak is unknown, 
although it could be modified VIP or PHI peptide, or perhaps 
is yet another member of the VIP family. The observation that 
it is detected by both VIP and PHI antisera suggests the latter 
possibility. On a phenyl HPLC column rat PLP also elutes as 
a single major peak separated from VIP, PLP, and secretin (see 
Fig. 4). 
Distribution of PHI and VIP in rat and porcine brain. Based 
on the chromatographic characterization data, it is likely that 
rat PLP is different from PHI-27. Until the sequence of rat 
PLP is known and its degree of cross-reactivity with the PHI- 
27 antiserum is determined, precise quantitation of PLP levels 
in rat brain cannot be performed. However, the PHI RIA can 
provide a good relative measure of the abundance of PLP 
peptides in different brain regions. 
The distribution of PLP and VIP was determined by RIA in 
major regions of rat and procine brain and in microdissected 
regions of rat brain. The data for the major regions of rat brain 
are presented in Table II. The distribution of PLP clearly 
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Figure 2. Sephadex G-50 chromatography of a rat brain extract eluted with 1% (v/v) acetic 
acid. Fractions of 2.0 ml were collected. The elution of a rat brain extract and synthetic PHI 
measured by RIA is compared to the elution of blue dextran (void volume marker) and Nan51 
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Figure 3. HPLC separation of VIP and PHI peptides 
of porcine (A) and rat (B) brain extracts in comparison 
with the elution of synthetic PHI or VIP detected opti- 
cally or by RIA, or secretin and motilin detected optically. 
This separation utilized the Cl&TEAP system described 
under “Materials and Methods.” 
FRACTION NUMBER 
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brain regions is very high, approaching that of cholecystokinin 
(Beinfeld et al., 1981). Like VIP, PLP is higher in cerebral 
cortex, hypothalamus, and the limbic system than it is in the 
thalamus and more caudal poritons of the brain. In most large 
areas of rat brain measured for PLP and VIP there is no 
statistical difference between either the concentration or the 
content of VIP and PLP. In the amygdala and cerebellum, the 
PLP concentration is higher than that of VIP, whereas in the 
mesencephalon, olfactory bulb, medulla, and retina the opposite 
is true. 
When the PLP and VIP concentration is compared in micro- 
punches of rat brain, local differences in VIP and PLP concen- 
ViP 
SEC c PHI 
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Figure 4. HPLC separation of a rat brain extract on a Waters 
phenyl column using the TFA system described under “Materials and 
Methods.” Elution of PHI and VIP were detected by RIA, secretin 
elution was detected optically. 
tration become more apparent, as is shown in Table III. In 
more than half of the areas examined, there was a significant 
difference between the concentration of VIP and PLP. In some 
areas the difference is quite dramatic: in the suprachiasmatic 
nucleus, the PLP concentration was 3.6 + 0.6 and VIP was 0.88 
f 0.05; in the posterior hypothalamus the VIP concentration 
was 0.34 + 0.04 and PLP was undetectable (<0.09). Neither 
VIP nor PLP is consistently the highest in all areas, although 
PLP is consistently higher than VIP in cerebral cortex and 
basal ganglia, whereas VIP is higher than PLP in thalamus 
and in most areas of the hypothalamus except the suprachias- 
matic and periventricular nuclei. 
In porcine brain, also, PLP concentrations also closely par- 
allel VIP concentration, and both PLP and VIP are substan- 
tially lower in porcine brain than in rat brain (Table IV). That 
porcine brain has substantially lower VIP levels than does rat 
brain has been reported previously (Fahrenkrug et al., 1978), 
although differences in extraction methods between rat and 
porcine brain used in the present study also account for some 
of the difference. 
Discussion 
Rat and porcine brain contain substantial quantities of a 
PHI-like peptide (PLP). Based on the Sephadex and HPLC 
results reported here and on the sequence data of Tatemoto et 
al. (1983), this porcine brain peptide is identical to PHI. In rat 
brain, the PLP is similar in molecular weight but either has 
some alteration in its amino acid sequence or has been post- 
translationally modified in a way which has rendered it less 
polar than synthetic PHI-27. Rat PLP is unlikely to be VIP, 
secretin, glucagon, GHRH, or PHM-27 since the PHI antise- 
rum detects them so poorly. The sequence of this rat PLP may 
be quite similar to that of PHI-27 since it has similar trypsin 
sensitivity and can be detected efficiently with a PHI-27 anti- 
serum. Work is in progress to determine the sequence of rat 
PLP, to resolve questions about whether it is a PHI-27-related 
peptide or another new member of the diverse VIP family. It 
appears that the PHI-27-like sequence is not strongly conserved 
if porcine and human PLP are known to be different and rat 
PLP appears to be different than either human or porcine. 
The PHI antiserum used in this study displays weak cross- 
reactivity with secretin (0.8%) and glucagon (0.5%); thus it is 
TABLE II 
Comparison of the distribution of PHI- and VIP-like immunoreactivity in brains of 200-gm male rats 
Data are expressed as picomoles of peptide per milligram of protein or as picomoles of peptide per brain region. Values are mean f SEM (N 
= $6). Statistical comparison between VIP and PHI values was performed with the two-tailed Student’s t test. 

















1.13 + 0.17 1.29 + 0.2 
0.83 + 0.08 0.56 + 0.05" 
0.46 f 0.04 0.43 + 0.02 
0.33 f 0.03 0.32 + 0.03 
0.30 + 0.03 0.26 f 0.02 
0.25 f 0.03 0.28 f 0.03 
0.25 2 0.006 0.28 f 0.01* 
0.13 f 0.04 0.20 f 0.02 
0.12 + 0.025 0.15 k 0.02 
0.08 f 0.006 0.17 zk 0.04 
0.06 + 0.009 0.06 f 0.003 
0.05 f 0.009 0.11 f 0.012* 
0.05 f 0.006 0.008 f 0.001' 
0.04 f 0.006 0.14 + 0.01’ 

















71.8 + 10.0 82.0 + 12.6 
2.9 f 0.3 2.0 f 0.2 
3.6 + 0.3 3.4 f 0.31 
0.47 + 0.03 0.47 f 0.05 
3.29 + 0.38 2.91 * 0.21 
0.75 + 0.07 0.87 + 0.3 
2.6 + 0.26 2.9 + 0.23 
0.16 k 0.05 0.26 & 0.03 
0.89 + 0.16 1.11 + 0.17 
0.19 f 0.04 0.32 + 0.04" 
0.42 f 0.06 0.45 f 0.04 
0.21 f 0.03 0.52 f 0.08' 
0.5 f 0.04 0.09 f 0.01" 
0.35 f 0.06 1.10 + 0.06' 
0.08 + 0.07 0.20 + 0.002" 
“p < 0.05. 
*p < 0.01. 
“p < 0.001. 
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TABLE III 
Comparison of the distribution of VIP and PHI immunoreactivity in 
microdissected region of the rat brain 
Brain Region PHI VIP PHI/VIP Ratio 
0.93 + 0.09 1.00 + 0.06 
1.13 + 0.15 0.99 + 0.12 
1.18 f 0.11” 0.75 + 0.10 
1.03 f 0.046 0.71 + 0.03 
0.93 + 0.1 0.61 -r- 0.03 
0.76 2 0.13 0.58 f 0.02 
0.82 + 0.08” 0.58 + 0.04 
3.6 + 0.6” 0.88 +- 0.05 
0.6 f 0.05 0.57 + 0.04 
0.41 f 0.09 0.46 rt 0.04 
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Medial geniculate nu- 
cleus 
Dorsal raphe nucleus 
Superior colliculus 
Inferior colliculus 
Substantia nigra pars 
reticulata 
0.14 f 0.03’ 0.40 f 0.08 
0.25 + 0.04 0.37 f 0.05 
0.09 + 0.02’ 0.36 + 0.05 
ND, <O.Ogd 0.34 + 0.04 
1.47 rf: 0.41’ 0.32 + 0.03 
0.07 f o.oo* 0.30 f 0.02 
0.24 f 0.10 0.27 IL 0.04 
ND, CO.125 0.26 + 0.06 
ND, co.05 0.23 + 0.02 
0.13 2 0.02’ 0.21 + 0.02 
0.18 + 0.02” 0.18 -t 0.05 
0.08 + 0.02’ 0.17 f 0.02 
0.18 + 0.02 0.17 + 0.02 
0.24 f 0.08 0.14 f 0.02 
0.08 + 0.02 0.12 + 0.01 
0.06 + 0.002* 0.08 + 0.001 
ND, co.02 0.06 -t 0.001 






































0.65 -t 0.05’ 0.42 f 0.02 
0.07 f 0.006’ 0.04 f 0.006 
0.15 f 0.04 0.11 + 0.04 
0.18 +- 0.03” 0.32 _+ 0.04 
0.03 + 0.006* 0.11 + 0.01 
0.15 f 0.02” 0.22 + 0.02 
0.25 f 0.02 0.21 +- 0.002 
0.26 -t 0.03 0.21 f 0.002 
0.23 f 0.06 0.21 + 0.002 
0.47 f 0.046 0.08 f 0.006 
0.12 +- 0.03 0.06 f 0.001 
0.03 + 0.01 0.04 f 0.001 
n’p < 0.05. 
*p < 0.001. 
= p < 0.02. 
d ND, nondetectable. The value that follows was calculated based on 
sample size and detection limit. 
‘p < 0.01. 
pmol/mg ofprotein 
conceivable that a small percentage of what is detected in the 
PHI RIA consists of cross-reacting secretin peptides known to 
be present in rat and porcine brain (O’Donohue et al., 1981). 
However, the levels of secretin are generally much lower than 
the levels of PHI, and areas which are high in secretin (e.g., 
thalamus) are low in PHI. Likewise the cerebral cortex, which 
is high in PHI, has the lowest secretin content of rat brain 
regions. Even in hypothalamus, where secretin is high, with 
0.8% cross-reactivity between PHI-27 and secretin, only 16 of 
2000 pg measured for PHI would be contributed by secretin. 
Glucagon can be expected to contribute even less to the tissue 
PHI levels measured because the cross-reactivity is lower than 
for secretin and the glucagon levels in the brain are even lower 
than those of secretin (Tager et al., 1980). 
The possibility that we are detecting as yet unknown mem- 
bers of the VIP-PHI-secretin-glucagon peptide family with the 
PHI RIA cannot, of course, be excluded. However, the obser- 
vation that the rat and porcine brain PHI-like material elutes 
as a single major peak on t.hree different HPLC systems makes 
this possibility unlikely. Minor peaks of PHI-like and VIP-like 
immunoreactivity were observed in porcine brain which may 
represent new members of this peptide family. The possibility 
that one or more of the minor high molecular weight peaks 
eluting from the Sephadex column is in fact a non-PHI, im- 
munologically related peptide cannot be excluded. 
The distribution of VIP and PHI is positively correlated in 
rat and porcine brain, even though rat brain has at least 5 times 
more VIP than porcine brain. In older (400 gm) rats where VIP 
levels are reduced (Beinfeld et al., 1983) relative to 200-gm rats 
(as in Table II), the PHI levels are also reduced proportionately 
(data not shown). In some brain nuclei (the suprachiasmatic 
and periventricular nuclei of the hypothalamus) PHI is 3 to 5 
times more abundant than VIP, whereas in other areas (pos- 
terior hypothalamus or ventromedial nucleus of the hypothal- 
amus) VIP is 3 to 4 times more abundant than PHI. Given the 
possibility that PHI and VIP occur in the same neurons and 
that they may arise from the same precursor, this difference in 
concentration could reflect local differential regulation of gene 
products, as in the case of the pro-opiomelanocortin precursor 
(Mains and Eipper, 1981), or differential regulation of mRNA 
splicing and processing or differential metabolism of the proc- 
essed peptides. Another possible explanation is that addition, 
as yet undiscovered, members of the VIP family of peptides 
exist which cross-react differentially with the VIP and PHI 
RIA in different brain regions, causing an apparent nonuniform 
distribution of VIP and PHI. 
Whether PHI and VIP are co-localized in the same neurons 
is still under investigation, and there have been positive (Chris- 
tofides et al. 1982a, b) and negative (Hokfelt et al., 1982) reports 
in specific brain areas. Hokfelt et al. (1982) report dense PHI 
fiber staining in the median eminence whereas VIP stains 
weakly there; also, PHI but not VIP antiserum stains cells in 
the paraventricular nucleus of the hypothalamus. We report 
here that, by RIA, the median eminence has measurable VIP 
levels (0.85 + 0.21 ng/mg of protein), whereas PHI is below the 
detection limit (cO.25). The VIP and PHI levels in the para- 
ventricular nucleus are similar (-1.5). The reasons for this 
discrepancy are not apparent, but since the PHI RIA is mark- 
edly less sensitive than the VIP RIA, the immunocytochemical 
technique of Hokfelt et al. (1982) may be more sensitive than 
the VIP RIA and can more easily detect PHI in the median 
eminence. The immunocytochemical techniques used by Hok- 
felt et al. (1982) may also have lacked the sensitivity to detect 
VIP and PHI in all brain regions. Differences in detectability 
between RIA and immunocytochemistry have been frequently 
observed in the past (Beinfeld and Palkovits, 1982, for exam- 
ple). 
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TABLE IV 
Comparison of VIP and PHI immunoreactivity in porcine brain regions 
Data are expressed as picomoles of peptide per gram of tissue or as picomoles of peptide per brain region. Values are mean f SEM (N = 3 to 
5). Statistical comparison was performed with a two-tailed Student’s t test. 
Brain Region PHI VIP 
PHI/VIP 
Ratio PHI VIP 
pmol/gm of wet wt. pmol/region 
Hippocampus 12.5 + 1.6 6.9 + 0.87” 1.81 39.2 + 2.8 23.2 f 4.7” 
Cerebral cortex 7.3 + 2.1 4.9 5 0.81 1.49 539.2 + 58.3 367.6 f 52.9 
Septum 6.1 f 2.1 9.5 + 2.0 0.64 4.5 f 1.3 7.1 -t 1.0 
Hypothalamus 1.8 -c 0.56 1.8 f 0.48 1.00 1.9 + 0.28 2.4 + 0.48 
Thalamus 1.1 + 0.22 1.0 + 0.21 1.10 0.85 f 0.09 0.84 + 0.18 
Medulla 1.0 + 0.13 0.69 + 0.21 1.45 2.6 f 0.47 1.71 f 0.48 
Striatum 0.85 f 0.09 1.38 Z!I 0.27 0.62 2.9 + 0.19 3.78 -t 1.26 
Pons 0.85 + 0.09 0.93 f 0.06 0.91 2.4 31 0.13 2.4 + 0.42 
Midbrain 0.66 + 0.09 1.17 + 0.12* 0.56 1.7 ir 0.19 3.24 f 0.54’ 
Cerebellum 0.09 -+ 0.003 0.21 f 0.02b 0.43 1.4 f 0.19 2.46 f 0.24” 
np < 0.05. 
*p < 0.01. 
‘p < 0.02. 
Preliminary binding data indicate that PHI-27 can potently 
inhibit the binding of iz51-labeled VIP to rat brain membranes, 
with an affinity in the nanomolar range. Whether rat brain 
PLP can also displace labeled VIP from its binding sites has 
not been determined but is under investigation. The ability of 
PHI-27 to competitively inhibit VIP binding has been reported 
in a number of other tissues (Bataille et al., 1980; Jensen et al., 
1982; Robberecht et al., 1982), which suggests that PHI could 
be an agonist or antagonist for VIP receptors. That PHI-27 
has VIP- and secretin like actions in carp retina (Watling and 
Dowling, 1983) and in a neuroblastoma cell line (Roth et al., 
1984) is suggestive of agonist rather than antagonist activity. 
These observations are suggestive of a possible role of PLPs as 
an endogenous VIP-like agonist or antagonist in the central 
nervous system. 
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